Le Lézard
Classified in: Health, Business
Subject: RLE

MedCore Announces the Acquisition of 86-Unit Senior Living Community in Dallas, TX


DALLAS, Oct. 11, 2022 /PRNewswire/ -- MedCore Partners has completed the acquisition of an 86-unit senior living community called The Grove on Forest Lane (formerly known as The Avenues of Park Forest) in North Dallas. The senior living community offers 70 assisted living and 16 memory care residences and marks MedCore's second acquisition in Texas but the first in the DFW market. The acquisition is MedCore's 19th nationwide.

"The MedCore team is especially pleased to add this community to our portfolio," said Sundeep Jeste, Senior Vice President of Seniors Housing Operations. "Its favorable location, combined with an infusion of capital for renovations, will provide an attractive destination for families seeking the convenience of North Dallas for their loved ones."

The renovation effort will include new interior and exterior signage, courtyard landscaping, common area upgrades, and apartment amenities enhancements. Senior By Design and a to-be-named general contractor are delivering the renovations.

The acquisition team hopes to leverage the project's tremendous occupancy growth potential and central location to hospital systems, recreational and lifestyle amenities to position it for steady value enhancement. The Dallas MSA is well-positioned for occupancy absorption going into 2023 based on population in-migration.

MedCore currently operates 19 senior living communities in Texas, Oklahoma, Arizona, Utah, Nevada, California, Washington, and Oregon. In addition, MedCore has two senior living projects under construction in Texas. This will bring their seniors housing portfolio to 21 assets with approximately 2,500 beds.

SOURCE MedCore Partners


These press releases may also interest you

at 20:15
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer's Disease (POLARIS-AD)
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...

at 19:34
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRAtm
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...

at 16:48
Marc Dubrick and Lisa Becharas Win St. Anthony's Triathlon
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...

at 16:30
CYTALUX Real-World Experience Presented at the American Association for Thoracic Surgery 104th Annual Meeting
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...

at 15:40
Brooks Breland Named Leading Lawn and Plant Health Care Expert
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...

at 12:00
OBiO Technology will showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

More news about Health...


News published on and distributed by: